FDC Launches Two Variants of Favipiravir for Covid-19 Treatment in India at Rs 55 Per Tablet

The DCGI had earlier approved the use of Favipiravir, an off patent, oral antiviral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms, FDC said.</p>

Read the Rest at News18

Leave a Reply

Your email address will not be published. Required fields are marked *